The race for solutions to Covid-19 is so big that Bloomberg has created a tracking page. Here's a synopsis of the companies listed:
Gilead Sciences is supplying Remdesivir, which was just approved by the FDA
Teva Pharmaceutical, Sanofi, Mylan NV, Natco Pharma, Novartis, Bayer and others are testing the generic anti-malarial drug hydroxychloroquine and chloroquine
Takeda Pharmaceutical is exploring convalescent plasma.
AstraZeneca, Eli Lilly, Regeneron Pharmaceuticals and others are developing monoclonal antibodies.
Zhejiang Hisun Pharmaceutical is testing the flu medicine Favipiravir.
GlaxoSmithKline and Vir Biotechnology are using CRISPR to find antibody targets.
Vaccines are crucial to ending the pandemic. There are more than 100 vaccines projects in some stage of development, according to the World Health Organization.
Moderna is testing mRNA-1273.
Johnson & Johnson is working an adenovirus-based vaccine and two other backups.
Inovio Pharmaceuticals is testing INO-4800, which activates the immune system.
BioNTech SE, Pfizer are developing BioNtech's BNT162 vaccine.
Sanofi and GlaxoSmithKline are collaborating to repurpose Sanofi's flu vaccine for Covid-19.
Oxford University and AstraZeneca are testing a spike protein vaccine.
CanSino Biologics is safety-testing a replication-defective mutant virus.
Novavax is also developing a spike vaccine.
China National Biotec Group is trialing an inactivated virus vaccine.
Sinovac Biotech is also developing an inactivated virus.
Imperial College London will soon be testing a recombinant spike protein vaccine.
These therapies don't directly treat or prevent the virus, but mitigate symptoms, such as difficulty breathing or severe inflammatory responses. The following are all testing anti-inflammatory products:
Regeneron Pharmaceuticals and Sanofi - Kevzara.
Roche Holding and Chugai Pharmaceutical - Actemra, alone or in combination with the flu drug Avigan.